Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Arcturus Therapeutics ( (ARCT) ).
On October 22, 2025, Arcturus Therapeutics announced interim results from its Phase 2 clinical trial of ARCT-032, an investigational mRNA therapy for cystic fibrosis, marking a significant step in its therapeutic development. Additionally, the company is involved in a legal dispute with AbbVie Inc. and others over trade secrets, and is working with CSL Seqirus on regulatory processes for KOSTAIVE, a self-amplifying mRNA vaccine, facing new FDA requirements for additional data.
The most recent analyst rating on (ARCT) stock is a Buy with a $49.00 price target. To see the full list of analyst forecasts on Arcturus Therapeutics stock, see the ARCT Stock Forecast page.
Spark’s Take on ARCT Stock
According to Spark, TipRanks’ AI Analyst, ARCT is a Neutral.
Arcturus Therapeutics’ overall stock score reflects significant financial challenges, despite positive technical indicators and promising corporate developments. The financial performance is the most significant factor, highlighting ongoing risks. However, positive earnings call sentiment and recent corporate achievements provide a balanced outlook.
To see Spark’s full report on ARCT stock, click here.
More about Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc. operates in the biotechnology industry, focusing on the development of mRNA-based therapies and vaccines. The company is involved in creating treatments for cystic fibrosis and has partnered with CSL Seqirus for the development of mRNA vaccines for infectious diseases, including COVID-19 and influenza.
Average Trading Volume: 753,102
Technical Sentiment Signal: Hold
Current Market Cap: $584.1M
Find detailed analytics on ARCT stock on TipRanks’ Stock Analysis page.